|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: COQ9 |
Gene summary for COQ9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | COQ9 | Gene ID | 57017 |
| Gene name | coenzyme Q9 | |
| Gene Alias | C16orf49 | |
| Cytomap | 16q21 | |
| Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | A0A024R6U3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57017 | COQ9 | C21 | Human | Oral cavity | OSCC | 7.35e-53 | 1.53e+00 | 0.2678 |
| 57017 | COQ9 | C30 | Human | Oral cavity | OSCC | 3.67e-36 | 1.66e+00 | 0.3055 |
| 57017 | COQ9 | C38 | Human | Oral cavity | OSCC | 2.90e-09 | 8.39e-01 | 0.172 |
| 57017 | COQ9 | C43 | Human | Oral cavity | OSCC | 7.12e-14 | 3.84e-01 | 0.1704 |
| 57017 | COQ9 | C46 | Human | Oral cavity | OSCC | 2.68e-32 | 7.24e-01 | 0.1673 |
| 57017 | COQ9 | C51 | Human | Oral cavity | OSCC | 1.24e-12 | 8.75e-01 | 0.2674 |
| 57017 | COQ9 | C57 | Human | Oral cavity | OSCC | 1.06e-16 | 6.82e-01 | 0.1679 |
| 57017 | COQ9 | C06 | Human | Oral cavity | OSCC | 2.35e-06 | 1.26e+00 | 0.2699 |
| 57017 | COQ9 | C08 | Human | Oral cavity | OSCC | 1.71e-25 | 5.88e-01 | 0.1919 |
| 57017 | COQ9 | C09 | Human | Oral cavity | OSCC | 2.21e-03 | 1.55e-01 | 0.1431 |
| 57017 | COQ9 | LN46 | Human | Oral cavity | OSCC | 1.11e-23 | 7.98e-01 | 0.1666 |
| 57017 | COQ9 | LP15 | Human | Oral cavity | LP | 1.15e-03 | 9.15e-01 | 0.2174 |
| 57017 | COQ9 | LP17 | Human | Oral cavity | LP | 1.22e-02 | 5.93e-01 | 0.2349 |
| 57017 | COQ9 | SYSMH1 | Human | Oral cavity | OSCC | 2.77e-09 | 2.77e-01 | 0.1127 |
| 57017 | COQ9 | SYSMH2 | Human | Oral cavity | OSCC | 2.88e-30 | 6.62e-01 | 0.2326 |
| 57017 | COQ9 | SYSMH3 | Human | Oral cavity | OSCC | 3.68e-33 | 7.88e-01 | 0.2442 |
| 57017 | COQ9 | SYSMH4 | Human | Oral cavity | OSCC | 2.17e-06 | 1.43e-01 | 0.1226 |
| 57017 | COQ9 | SYSMH5 | Human | Oral cavity | OSCC | 5.39e-09 | 3.08e-01 | 0.0647 |
| 57017 | COQ9 | SYSMH6 | Human | Oral cavity | OSCC | 1.70e-10 | 3.79e-01 | 0.1275 |
| 57017 | COQ9 | P5_S10_cSCC | Human | Skin | cSCC | 1.17e-04 | 1.29e-01 | -0.299 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000611920 | Esophagus | HGIN | oxidative phosphorylation | 69/2587 | 141/18723 | 1.37e-23 | 2.05e-20 | 69 |
| GO:000906020 | Esophagus | HGIN | aerobic respiration | 81/2587 | 189/18723 | 1.07e-22 | 9.26e-20 | 81 |
| GO:004603427 | Esophagus | HGIN | ATP metabolic process | 101/2587 | 277/18723 | 1.53e-21 | 1.02e-18 | 101 |
| GO:000609120 | Esophagus | HGIN | generation of precursor metabolites and energy | 145/2587 | 490/18723 | 3.41e-20 | 2.04e-17 | 145 |
| GO:004533320 | Esophagus | HGIN | cellular respiration | 86/2587 | 230/18723 | 2.41e-19 | 1.20e-16 | 86 |
| GO:001598020 | Esophagus | HGIN | energy derivation by oxidation of organic compounds | 105/2587 | 318/18723 | 1.16e-18 | 4.99e-16 | 105 |
| GO:004277320 | Esophagus | HGIN | ATP synthesis coupled electron transport | 49/2587 | 95/18723 | 2.21e-18 | 7.36e-16 | 49 |
| GO:004277520 | Esophagus | HGIN | mitochondrial ATP synthesis coupled electron transport | 49/2587 | 95/18723 | 2.21e-18 | 7.36e-16 | 49 |
| GO:002290420 | Esophagus | HGIN | respiratory electron transport chain | 51/2587 | 114/18723 | 9.63e-16 | 2.41e-13 | 51 |
| GO:001964620 | Esophagus | HGIN | aerobic electron transport chain | 43/2587 | 87/18723 | 1.98e-15 | 4.41e-13 | 43 |
| GO:002290020 | Esophagus | HGIN | electron transport chain | 66/2587 | 175/18723 | 2.21e-15 | 4.73e-13 | 66 |
| GO:000612020 | Esophagus | HGIN | mitochondrial electron transport, NADH to ubiquinone | 28/2587 | 51/18723 | 5.72e-12 | 7.30e-10 | 28 |
| GO:19016614 | Esophagus | HGIN | quinone metabolic process | 13/2587 | 40/18723 | 2.04e-03 | 2.13e-02 | 13 |
| GO:0006091110 | Esophagus | ESCC | generation of precursor metabolites and energy | 331/8552 | 490/18723 | 3.86e-23 | 8.45e-21 | 331 |
| GO:0045333110 | Esophagus | ESCC | cellular respiration | 173/8552 | 230/18723 | 4.53e-20 | 5.99e-18 | 173 |
| GO:0009060110 | Esophagus | ESCC | aerobic respiration | 145/8552 | 189/18723 | 2.16e-18 | 2.21e-16 | 145 |
| GO:0015980110 | Esophagus | ESCC | energy derivation by oxidation of organic compounds | 220/8552 | 318/18723 | 1.20e-17 | 1.09e-15 | 220 |
| GO:0022900110 | Esophagus | ESCC | electron transport chain | 133/8552 | 175/18723 | 2.18e-16 | 1.67e-14 | 133 |
| GO:0046034111 | Esophagus | ESCC | ATP metabolic process | 189/8552 | 277/18723 | 1.99e-14 | 1.04e-12 | 189 |
| GO:0006119111 | Esophagus | ESCC | oxidative phosphorylation | 106/8552 | 141/18723 | 8.19e-13 | 3.63e-11 | 106 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| COQ9 | SNV | Missense_Mutation | c.76N>A | p.Ala26Thr | p.A26T | O75208 | protein_coding | tolerated_low_confidence(0.61) | benign(0) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| COQ9 | SNV | Missense_Mutation | c.743N>T | p.Ala248Val | p.A248V | O75208 | protein_coding | tolerated(0.07) | benign(0.068) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| COQ9 | SNV | Missense_Mutation | c.342N>A | p.His114Gln | p.H114Q | O75208 | protein_coding | deleterious(0.02) | probably_damaging(0.949) | TCGA-AA-3976-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | folinic | CR | |
| COQ9 | SNV | Missense_Mutation | rs201097286 | c.467G>A | p.Arg156Gln | p.R156Q | O75208 | protein_coding | tolerated(0.49) | benign(0.003) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| COQ9 | SNV | Missense_Mutation | rs763626877 | c.259G>A | p.Gly87Ser | p.G87S | O75208 | protein_coding | tolerated(0.05) | probably_damaging(0.999) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| COQ9 | SNV | Missense_Mutation | c.275A>G | p.Asp92Gly | p.D92G | O75208 | protein_coding | tolerated(0.25) | benign(0) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| COQ9 | SNV | Missense_Mutation | c.227N>T | p.Ser76Phe | p.S76F | O75208 | protein_coding | tolerated(0.57) | benign(0.001) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| COQ9 | insertion | Frame_Shift_Ins | novel | c.481_482insA | p.Leu161HisfsTer38 | p.L161Hfs*38 | O75208 | protein_coding | TCGA-AG-A00Y-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
| COQ9 | SNV | Missense_Mutation | novel | c.697N>T | p.Asp233Tyr | p.D233Y | O75208 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| COQ9 | SNV | Missense_Mutation | novel | c.98N>C | p.Val33Ala | p.V33A | O75208 | protein_coding | tolerated_low_confidence(0.69) | benign(0) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |